naquotinib + midazolam
Phase 1Completed 2 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small-Cell Lung Cancer (NSCLC)
Conditions
Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations
Trial Timeline
Apr 9, 2014 → Feb 11, 2019
NCT ID
NCT02113813About naquotinib + midazolam
naquotinib + midazolam is a phase 1 stage product being developed by Astellas Pharma for Non-Small-Cell Lung Cancer (NSCLC). The current trial status is completed. This product is registered under clinical trial identifier NCT02113813. Target conditions include Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations.
What happened to similar drugs?
7 of 20 similar drugs in Non-Small-Cell Lung Cancer (NSCLC) were approved
Approved (7) Terminated (6) Active (9)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02113813 | Phase 1 | Completed |
Competing Products
20 competing products in Non-Small-Cell Lung Cancer (NSCLC)